» Articles » PMID: 33543354

Precursor Fractions of Neurotensin and Enkephalin Might Point to Molecular Mechanisms of Cancer Risk Modulation During a Lifestyle-intervention in Germline BRCA1/2 Gene Mutation Carriers

Abstract

Background: Germline BRCA1/2 mutation carriers (gBMC) face increased cancer risks that are modulated via non-genetic lifestyle factors whose underlying molecular mechanisms are unknown. The peptides Neurotensin (NT) and Enkephalin (ENK)-involved in tumorigenesis and obesity-related diseases-are of interest. We wanted to know whether these biomarkers differ between gBMC and women from the general population and what effect a 1-year lifestyle-intervention has in gBMC.

Methods: The stable precursor fragments pro-NT and pro-ENK were measured at study entry (SE), after 3 and 12 months for 68 women from LIBRE-1 (a controlled lifestyle-intervention feasibility trial for gBMC involving structured endurance training and the Mediterranean Diet). The SE values were compared with a cohort of the general population including female subjects with and without previous cancer disease, non-suggestive for hereditary breast and ovarian cancer (OMA-reference). For LIBRE-1, we analysed the association between the intervention-related change in the two biomarkers and certain lifestyle factors.

Results: At SE, gBMC had a higher median pro-NT than OMA-reference (in the subgroups with previous cancer 117 vs. 91 pmol/L, p = 0.002). Non-diseased gBMC had lower median pro-ENK levels when compared to the non-diseased reference group. VO2peak and pro-NT 1-year change in LIBRE-1 were inversely correlated (r = - 0.435; CI - 0.653 to - 0.151; p = 0.004). Pro-ENK correlated positively with VO2peak at SE (r = 0.323; CI 0.061-0.544; p = 0.017). Regression analyses showed an inverse association of 1-year changes for pro-NT and Omega-6/Omega-3 (Estimate: - 37.9, p = 0.097/0.080) in multivariate analysis.

Conclusion: Our results give first indications for lifestyle-related modification particularly of pro-NT in gBMC.

Citing Articles

IL-4, IL-7, IL-9, NT, NRP1 May Be Useful Markers in the Diagnosis of Endometrial Cancer.

Kozlowski M, Borzyszkowska D, Lerch N, Turon-Skrzypinska A, Tkacz M, Lubikowski J Biomolecules. 2024; 14(9).

PMID: 39334861 PMC: 11430137. DOI: 10.3390/biom14091095.


Predictors of cardiopulmonary fitness in cancer-affected and -unaffected women with a pathogenic germline variant in the genes BRCA1/2 (LIBRE-1).

Berling-Ernst A, Yahiaoui-Doktor M, Kiechle M, Engel C, Lammert J, Grill S Sci Rep. 2022; 12(1):2907.

PMID: 35190584 PMC: 8861033. DOI: 10.1038/s41598-022-06913-1.

References
1.
Eliassen A, Colditz G, Rosner B, Willett W, Hankinson S . Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006; 296(2):193-201. DOI: 10.1001/jama.296.2.193. View

2.
Ratner C, Skov L, Raida Z, Bachler T, Bellmann-Sickert K, Le Foll C . Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in Gastric Bypass Surgery. Endocrinology. 2016; 157(9):3482-92. DOI: 10.1210/en.2016-1329. View

3.
Ferrini K, Ghelfi F, Mannucci R, Titta L . Lifestyle, nutrition and breast cancer: facts and presumptions for consideration. Ecancermedicalscience. 2015; 9:557. PMC: 4531134. DOI: 10.3332/ecancer.2015.557. View

4.
Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter M, Ezzati M . Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2017; 6(2):95-104. PMC: 5805864. DOI: 10.1016/S2213-8587(17)30366-2. View

5.
Zhao D, Plotnikoff N, Griffin N, Song T, Shan F . Methionine enkephalin, its role in immunoregulation and cancer therapy. Int Immunopharmacol. 2016; 37:59-64. DOI: 10.1016/j.intimp.2016.02.015. View